Nutex Health, Inc. (NUTX)
Valuation Overview•Is Nutex Health, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 87/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
NUTX exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 38.0% ROIC). This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (58.6% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 31.4% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $216.5M | +82.4% | +58.6% | +26.1% | — | |
| EBITDA | $86.8M | — | — | — | — | |
| Net Income | $46.8M | +35.7% | — | — | +96.2% | |
| EPS (Diluted) | $6.52 | +7.9% | — | -15.8% | +74.3% | |
| Free Cash Flow | $75.5M | +1077.9% | +89.7% | +57.3% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 47.5% | 35.2% | 33.4% | -66.2% |
| Operating Margin | 31.4% | 15.3% | -17.6% | -1401.3% |
| Net Margin | 11.0% | 0.2% | -30.6% | -232.0% |
| FCF Margin | 30.7% | 9.7% | 17.3% | -198.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $3.99 | $6.52 | +63.4% | ||
| Q1'26 | $5.56 | $1.61 | -71.0% | ||
| Q4'25 | $1.81 | $7.76 | +328.7% | ||
| Q4'25 | $-1.43 | $-2.95 | -105.8% | ||
| Q4'25 | $-5.43 | $-3.02 | +44.3% | ||
| Q2'25 | $3.04 | $2.56 | -15.8% | ||
| Q1'25 | $-0.12 | $11.12 | +9366.7% | ||
| Q4'24 | $-0.24 | $-1.72 | -616.7% |
Total return is +26.5% (1Y), outperforming the benchmark by +1.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +1.6% | -7.7% | — |
| 1Y | +26.5% | +1.5% | — |
| 3YCAGR | +33.4% | +12.6% | — |
| 5YCAGR | -52.1% | -64.9% | — |
| 10YCAGR | -30.8% | -44.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Nutex Health, Inc. (NUTX) valuation, health, and returns.
Based on peer relative multiples, Nutex Health, Inc. appears Cheap versus peers compared to industry peers.
Nutex Health, Inc. has multiple valuation anchors: Peer Relative Fair Value: $346.41 | Wall Street Analyst Target: $235.00 (implying +56.1% upside). A convergence of these signals offers higher conviction.
Nutex Health, Inc. displays excellent financial health with a composite quality score of 87/100, supported by a Altman Z-Score of 2.7 (grey zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 38.0%.
Nutex Health, Inc. returns capital via buybacks instead of dividends, carrying a 0.6% buyback yield and reducing outstanding shares by +32.5% in the last 12 months.
Nutex Health, Inc.'s current growth trajectory is Accelerating. The company achieved +82.4% 1Y revenue growth and +7.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +58.6%.
Wall Street consensus is Buy based on 2 analysts, beating EPS expectations in 50% of recent quarters with a 1-quarter streak. The consensus price target represents a +56.1% change from current levels.
Investment risks for Nutex Health, Inc. include: -54.3% 1-year max drawdown, high beta (1.91x market volatility). Volatility risk is characterized by a beta of 1.91x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.